IMPORTANT SAFETY INFORMATION | Prescribing Information | Send to a Colleague | MICARDIS Patient Web site
Hypertension Medical Events Calendar — Micardis® (Telmisartan) Tablets

Medical Events Calendar

For the most current information on events listed below, please contact the sponsoring organizations.

FEBRUARY 24-26, 2010 — SAN ANTONIO, TEXAS
American Heart Association/American Stroke Association
International Stroke Conference 2010

MARCH 14-16, 2010 — ATLANTA, GEORGIA
American College of Cardiology
Acc.10, 59th Annual Scientific Session and i2 Summit

MAY 1-4, 2010 — NEW YORK, NEW YORK
American Society of Hypertension
25th Annual Scientific Meeting and Exposition

JUNE 16-19, 2010 — BEIJING, CHINA
World Heart Federation
World Congress of Cardiology Scientific Sessions 2010

JUNE 18-20, 2010 — OSLO, NORWAY
European Society of Hypertension
20th European Meeting on Hypertension

JUNE 25-29, 2010 — ORLANDO, FLORIDA
American Diabetes Association
70th Scientific Sessions

JULY 24-27, 2010 — VANCOUVER, CANADA
International Academy of Cardiology
15th World Congress on Heart Disease Annual Scientific Sessions 2010

AUGUST 28-SEPTEMBER 1, 2010 — STOCKHOLM, SWEDEN
European Society of Cardiology
ESC Congress 2010

SEPTEMBER 26-30, 2010 — VANCOUVER, CANADA
International Society of Hypertension
23rd Annual Scientific Meeting

OCTOBER 13-16, 2010 — WASHINGTON, D.C.
American Heart Association
High Blood Pressure Research 2010 Scientific Sessions

NOVEMBER 16-21, 2010 — DENVER, COLORADO
American Society of Nephrology
ASN Renal Week 2010

Patient Reimbursement

Instant answers to your
reimbursement questions

Simply select your state. Your results will show available coverage and any restrictions that may apply.

* Only Micardis® (telmisartan) 80-mg Tablets are indicated for cardiovascular risk reduction. All other MICARDIS and Micardis® HCT (telmisartan and hydrochlorothiazide) Tablets dosages are indicated for the treatment of hypertension only. MICARDIS 80 mg is indicated for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take ACE inhibitors. High risk for cardiovascular events can be evidenced by a history of coronary artery disease, peripheral arterial disease, stroke, transient ischemic attack or high-risk diabetes (insulin-dependent or non-insulin-dependent) with evidence of end-organ damage. MICARDIS can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). Studies of telmisartan in this setting do not exclude that it may not preserve a meaningful fraction of the effect of the ACE inhibitor to which it was compared. Consider using the ACE inhibitor first, and, if it is stopped for cough only, consider re-trying the ACE inhibitor after the cough resolves. Use of telmisartan with an ACE inhibitor is not recommended.1

† Dosage must be individualized. In the treatment of hypertension, the usual starting dose of MICARDIS Tablets is 40 mg once a day. Blood pressure response is dose-related over the range of 20-80 mg. For patients who need even greater efficacy, MICARDIS HCT is available in 40/12.5-mg, 80/12.5-mg, and 80/25-mg tablets. Available as a unit dose. In the treatment of cardiovascular risk reduction, the recommended dose of MICARDIS is 80 mg once a day. It is not known whether doses lower than 80 mg of telmisartan are effective in reducing the risk of cardiovascular morbidity and mortality. When initiating MICARDIS therapy for cardiovascular risk reduction, monitoring of blood pressure is recommended and, if appropriate, adjustment of medications that lower blood pressure may be necessary.1


Return To Top Micardis Black Box Warning Micardis HCT Black Box Warning TWYNSTA Black Box Warning


Boehringer Ingelheim

Copyright © 2009 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved.
Use of this Site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Policy.
12/09   MC67669